PMID- 10323405
OWN - NLM
STAT- MEDLINE
DCOM- 19990527
LR  - 20161124
IS  - 0021-972X (Print)
IS  - 0021-972X (Linking)
VI  - 84
IP  - 5
DP  - 1999 May
TI  - A new contributing factor to polycystic ovary syndrome: the genetic variant of
      luteinizing hormone.
PG  - 1711-5
AB  - Although the etiology of polycystic ovary syndrome (PCOS) is still unclear, LH is
      considered to play a central role in its pathogenesis. An immunologically
      anomalous form of LH, with two point mutations in the LHbeta gene, has been
      recently described. This genetic variant of LH (v-LH), of wide geographic
      distribution, is functionally different from wild-type (wt) LH. To assess the
      role of the v-LH in PCOS, we analyzed its frequency in groups of PCOS patients
      from Finland, The Netherlands, the United Kingdom, and the United States. The LH 
      status was determined by two immunofluorometric assays from a total of 1466
      subjects. The carrier frequency of the v-LH allele in the whole study population 
      was 18.5%, being highest (28.9%) in Finland and lowest (11.2%) in The
      Netherlands. In the individual countries, the frequency of v-LH was similar in
      obese and nonobese controls, but in The Netherlands and Finland, it was 5- to
      7-fold lower in obese PCOS subjects compared with that in the other groups
      (2-4.5% vs. 10.3-33.3%; P < 0.05). A similar tendency was found in the United
      States (5.7% vs. 11.1-25.0%), but not in the United Kingdom. The overall high
      prevalence of v-LH in healthy women and women with PCOS suggests that it is
      compatible with fertility. The similar frequency of v-LH in healthy nonobese and 
      obese women indicates that obesity per se is not related to the variant. In
      contrast, the lower frequency of v-LH in obese PCOS patients suggests that v-LH
      somehow protects obese women from developing symptomatic PCOS. However, the
      regional differences in this finding between patients with apparently similar
      diagnostic criteria emphasizes the multifactorial nature of this syndrome, and
      that its pathogenesis may vary according to the genetic background. Although the 
      definitive role of v-LH in PCOS remains to be proven, its determination may
      improve the prediction of risk of PCOS, especially in obese women.
FAU - Tapanainen, J S
AU  - Tapanainen JS
AD  - Department of Obstetrics and Gynecology, University of Oulu, Finland.
      juha.tapanainen@oulu.fi
FAU - Koivunen, R
AU  - Koivunen R
FAU - Fauser, B C
AU  - Fauser BC
FAU - Taylor, A E
AU  - Taylor AE
FAU - Clayton, R N
AU  - Clayton RN
FAU - Rajkowa, M
AU  - Rajkowa M
FAU - White, D
AU  - White D
FAU - Franks, S
AU  - Franks S
FAU - Anttila, L
AU  - Anttila L
FAU - Pettersson, K S
AU  - Pettersson KS
FAU - Huhtaniemi, I T
AU  - Huhtaniemi IT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 9002-67-9 (Luteinizing Hormone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Female
MH  - Finland/epidemiology
MH  - Fluorescent Antibody Technique
MH  - Gene Frequency
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - Luteinizing Hormone/blood/*genetics
MH  - Netherlands/epidemiology
MH  - Obesity/blood/genetics
MH  - Polycystic Ovary Syndrome/epidemiology/*genetics
MH  - Retrospective Studies
MH  - United Kingdom/epidemiology
MH  - United States/epidemiology
EDAT- 1999/05/14 00:00
MHDA- 1999/05/14 00:01
CRDT- 1999/05/14 00:00
PHST- 1999/05/14 00:00 [pubmed]
PHST- 1999/05/14 00:01 [medline]
PHST- 1999/05/14 00:00 [entrez]
AID - 10.1210/jcem.84.5.5702 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 1999 May;84(5):1711-5. doi: 10.1210/jcem.84.5.5702.